JackLeckerman’s Post

Do you want to discover how biosimilars are revolutionizing healthcare in Brazil? 🧐 Perla Villani Borges, Liana Dalolli, and Marcela Amaral Pontes will be speaking at Biosimilars LatAm - Brazil 2024, sharing insights on how biosimilars are generating significant savings, improving access to treatments, and fostering competition in the pharmaceutical market 💵🏥 Don’t miss this opportunity to learn about the economic benefits of biosimilars and their role in the Brazilian healthcare system in just a few days. 🗓️ Date: August 21-22, 2024 📍 Venue: Pullman Ibirapuera #SãoPaulo Hotel You’re still in time to register and join us for this enriching experience! https://lnkd.in/d5RTHdk2 If you are affiliated with any of the following organizations, please contact us for a discount code: 🤝 ABIFINA, ABIQUIFI, ABRACRO, Alianza de CROs de Mexico (ACROM), ALANAC - Associação dos Laboratórios Farmacêuticos Nacionais, AMELAF, Amepres México, CANIFARMA, CAPGEN - Cámara Argentina de Productores de Medicamentos Hospitalarios, IGBA - International Generic and Biosimilar medicines Association, PróGenéricos, SINDIFARGO, União Farmacêutica de São Paulo - UNIFAR . #BiosimilarsForum #Brazil2024 #CostSavings #MarketDynamics #HealthcareAccess

Health Technology Assessment Unites Nordic Countries: Formation of Joint Nordic HTA-Bodies The formation of the Joint Nordic HTA-Bodies (JNHB) marks a significant advancement in health technology assessment (HTA) collaboration in the Nordic region, now including Denmark and Iceland alongside Finland, Norway, and Sweden. To celebrate, JNHB invited industry associations, decision-makers, and stakeholders to a launch event unveiling their new website, which provides detailed guidance for Health Technology Developers. Initially a grassroots initiative, FINOSE expanded and rebranded to JNHB, formalized through a Memorandum of Understanding signed by the Lægemiddelstyrelsen (Danish Medicines Agency), Finnish Medicines Agency Fimea - Lääkealan turvallisuus- ja kehittämiskeskus Fimea, Landspítali - The National University Hospital of Iceland, Norwegian Medical Products Agency, and Swedish The Dental and Pharmaceutical Benefits Agency, TLV. For more details please click the link! https://lnkd.in/eUKmdp_a #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

On December 5 in Brussels, the 8th Multistakeholder Event on biosimilars took place, with the participation of Agencja Oceny Technologii Medycznych i Taryfikacji as part of the #AUGMENT Biosimilars consortium, implementing the recently launched an EU4Health biosimilar capacity-building project. 🌍💉 The project aims to encourage biosimilar uptake through a comprehensive multi stakeholder approach by generating evidence, enhancing knowledge, and building capacity. 📚🔬   The event aimed for mixed participation of key stakeholder groups, which may be represented by European competent authorities, health service providers, patient and civil societies, pharmaceutical industry, academics as well EU and international institutions (#WHO, #OECD). 🤝🏥   During this meeting Elżbieta Kuriata, Ph.D. presented the preliminary results of the work carried out by #AOTMiT. In addition she led a group session on the stakeholder perspective on the project. 👩🔬   #Biosimilars #EU4Health #Healthcare #GlobalHealth

—- National standards for timeliness in Access to Novel Medicines in Indonesia : A Call for Action. The recent National Formulary (Fornas) Review has highlighted the significant imbalance between the number of Health Technology Assessments (HTAs) required and the technical capacity available within the country. Local academic institutions are currently facing a substantial backlog of over a hundred studies that need to be conducted. Meanwhile, new products that are standard of care in other parts of the world are not being included in the national formulary and covered by BPJS. Although Indonesia has expressed its intention to increasingly rely on HTA for the selection of JKN lists and benefit packages, the lack of human resources and insufficient financial support for HTA remain the biggest obstacles. Given the limited technical resources, allowing industry submissions could expedite the evaluation of novel medicines. However, this requires a transparent process to review submissions for their suitability in the local context. Additionally, it is necessary to assess whether further resources are needed to manage industry engagement, analyze submissions, and provide support to pharmaceutical companies throughout the submission process. International Pharmaceutical Manufacturers Group (IPMG) is leading this call for action. Its members have pledged to work with stakeholders to shape action and implementation toward institutionalizing HTA. A comprehensive effort from all parties is essential if we are to effectively address these challenges and strengthen HTA's role as a vital component of Indonesia’s health system. We owe it to our patients. We owe it to our nation. #access #innovation #HTA #UHC #patients #standardofcare

🌍💊 The 59th issue of the IPA CPD e-Times takes you to Bosnia and Herzegovina! Dive into Enisa Salihefendić and Ana Zovko's article exploring: 🔹 The decentralized structure of healthcare 🔹 Pharmacy’s vital role in public health 🔹 Efforts to align with global standards Despite challenges, pharmacists in Bosnia and Herzegovina stand strong as pillars of accessible care. 💙✨ Read more: https://bit.ly/3AL3bHi Indian Pharmaceutical Association || Manjiri Gharat || Raj Vaidya || #IPA #IPA_CPD #59thEtimes #GlobalPharmacy #BosniaPharmacy

Accord Healthcare Receives EC Marketing Authorization for Imuldosa® (DMB-3115) Accord Healthcare is excited to announce that the European Commission has granted marketing authorization for Imuldosa® (DMB-3115), a biosimilar to Stelara® (ustekinumab). This approval covers all 27 EU member states, plus Iceland, Norway, and Liechtenstein, following a positive opinion from the EMA's CHMP. Imuldosa® is indicated for immune-mediated inflammatory diseases and has demonstrated therapeutic equivalence to Stelara® in a Phase III clinical trial. This approval paves the way for its launch in the EU market, valued at approximately €2.9 billion. #Biosimilars #Imuldosa #Stelara #EUApproval #Healthcare #Autoimmune #Innovation #Pharma

"Market Access Challenges and Opportunities for #Biosimilars in Latin America," at the upcoming Biosimilars LatAm - Europe 2024 Online Forum on June 19-21. Latin America presents a dynamic landscape for biosimilar #marketaccess. Leading the way, Brazil, Mexico, and Argentina have robust regulatory frameworks but face challenges such as pricing and reimbursement policies. Colombia's tender-based system fosters market competition, while Chile emphasizes cost-effectiveness evaluations. Despite these hurdles, the region offers substantial opportunities for biosimilar penetration, fueled by the increasing demand for affordable biologic therapies and evolving regulatory environments. Featured Speakers: 🔹 Rafael Gual Cosío, General Director at CANIFARMA, Mexico 🔹 Marcela Amaral Pontes, Access Manager at Sindusfarma - Industry Syndicate of Pharmaceutical Products , Brazil Gain insights from industry experts and navigate the complexities of the Latin American biosimilar market. 🔗 Register now to secure your spot and benefit from better pricing until May 31! https://lnkd.in/gizVMKtb If you are affiliated with any of the following organizations, reach out for a discount code: 🤝 ABIQUIFI, Asociación Colombiana de Farmacovigilancia, Alianza de CROs de Mexico (ACROM), ALANAC - Associação dos Laboratórios Farmacêuticos Nacionais, Asociación de Médicos y Profesionales Especialistas en la Industria Farmacéutica AC, AMELAF, Amepres México, AseBio - Asociación Española de Bioempresas, ASINFAR, Assobiotec, BioSim, CANIFARMA, CAPGEN - Cámara Argentina de Productores de Medicamentos Hospitalarios, hollandbio, P-BIO - Associação Portuguesa de Bioindústria, PróGenéricos, SEBiot - Sociedad Española de Biotecnología, SINDIFARGO, União Farmacêutica de São Paulo UNIFAR #BiosimilarsLatAm #Europe2024 #Biotech #MarketAccess #Innovation #RegulatoryInsights

In the article "Notre proposition concrète d’un pôle public du médicament" published in September 2023 in Les Cahiers de Santé Publique et de Protection Sociale, a journal edited by the FONDATION GABRIEL PERI, Maryse Montangon, from the Parti Communiste Français (PCF), explains the party's 20-year-old proposal for the creation of a public pharmaceutical hub, conceived as an alternative to detach medications from the financial sphere and turn them into a universal common good. In her words: “It is necessary to reaffirm our country's independence in health matters. The pressure exerted by the markets on the supply of medicines also highlights the need for France to ensure its health sovereignty.” 🔗Check out the full article (in French): https://lnkd.in/djNj5ifm #PPfE #PublicPharma #publicpharmaeurope #publicpharmaforeurope

"Market Access Challenges and Opportunities for #Biosimilars in Latin America," at the upcoming Biosimilars LatAm - Europe 2024 Online Forum on June 19-21. Latin America presents a dynamic landscape for biosimilar #marketaccess. Leading the way, Brazil, Mexico, and Argentina have robust regulatory frameworks but face challenges such as pricing and reimbursement policies. Colombia's tender-based system fosters market competition, while Chile emphasizes cost-effectiveness evaluations. Despite these hurdles, the region offers substantial opportunities for biosimilar penetration, fueled by the increasing demand for affordable biologic therapies and evolving regulatory environments. Featured Speakers: 🔹 Rafael Gual Cosío, General Director at CANIFARMA, Mexico 🔹 Marcela Amaral Pontes, Access Manager at Sindusfarma - Industry Syndicate of Pharmaceutical Products , Brazil 🔹 Moderated by Ignacio Demarco, Commercial Manager LATAM at mAbxience, Argentina Gain insights from industry experts and navigate the complexities of the Latin American biosimilar market. 🔗 Register now to secure your spot! https://lnkd.in/gizVMKtb If you are affiliated with any of the following organizations, reach out for a discount code: 🤝 ABIQUIFI, Asociación Colombiana de Farmacovigilancia, Alianza de CROs de Mexico (ACROM), ALANAC - Associação dos Laboratórios Farmacêuticos Nacionais, Asociación de Médicos y Profesionales Especialistas en la Industria Farmacéutica AC, AMELAF, Amepres México, AseBio - Asociación Española de Bioempresas, ASINFAR, Assobiotec, BioSim, CANIFARMA, CAPGEN - Cámara Argentina de Productores de Medicamentos Hospitalarios, hollandbio, P-BIO - Associação Portuguesa de Bioindústria, PróGenéricos, SEBiot - Sociedad Española de Biotecnología, SINDIFARGO, União Farmacêutica de São Paulo UNIFAR #BiosimilarsLatAm #Europe2024 #Biotech #Innovation #RegulatoryInsights

Pharmaceutical Services Programme, Ministry of Health Malaysia will organize the 12th National Pharmacy Research and Development (R&D) Conference 2024 on August 19 – 21. The theme of this conference is "Unity for Medicine Security: Collaborative Solutions for a Safer Future." The conference will serve as a platform to foster more future collaborations and cross-sector partnerships among all stakeholders involved throughout the pharmaceutical product lifecycle within the country and the region. More on the objective of this conference via the link below; https://lnkd.in/gFdKdqDc #NPRA #MOH #regulatoryupdate #regulatoryaffairs #safety #regulations… ‎Read more